Начало・Списък с акции・Kura Oncology Inc

Kura Oncology Inc

Затворен

СекторЗдравеопазване

9.51 3.03

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.49

Максимум

9.58

Ключови измерители
By Trading Economics
Приходи	7.7M -73M
Продажби	929K 18M
EPS	-0.828
Марж на печалбата	-401.495
Служители	260
EBITDA	13M -73M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+193.73% upside

Дивиденти
By Acuity
Следващи печалби	12.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-28M 816M
Предишно отваряне	6.48
Предишно затваряне	9.51

Настроения в новините

By Acuity

37%

63%

111 / 340 Класиране в Healthcare

Kura Oncology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.08.2026 г., 23:36 ч. UTC

Kura Oncology Inc shares are lower in after-market hours, retracing from earlier gains. The stock remains below its 20-day moving average.

6.08.2026 г., 21:02 ч. UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close amid positive sentiment in the broader market.

5.08.2026 г., 19:26 ч. UTC

News

Kura Oncology Inc shares are lower today amid ongoing market volatility. The company will report second-quarter 2026 results after the market close on August 12.

4.08.2026 г., 19:36 ч. UTC

Kura Oncology Inc shares are higher today, continuing an upward trend since Monday. Broader market reactions follow a decline in U.S. core factory orders.

3.08.2026 г., 23:01 ч. UTC

Kura Oncology Inc. shares are higher in after-market trading, reflecting notable gains since Monday's close, despite no specific news to explain the increase.

31.07.2026 г., 21:01 ч. UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable rise since Friday's close despite remaining below the 20-day moving average.

30.07.2026 г., 19:49 ч. UTC

Kura Oncology Inc shares are higher Thursday, continuing a recent upward trend despite no specific news. The stock has rebounded from earlier session lows.

29.07.2026 г., 19:22 ч. UTC

Macro Event

Kura Oncology shares are lower, extending a six-session decline amid market volatility following the Federal Reserve's interest rate decision.

28.07.2026 г., 20:03 ч. UTC

Event

Kura Oncology shares are lower despite positive Phase 1a trial results for darlifarnib plus cabozantinib, reflecting broader market pressures.

27.07.2026 г., 20:07 ч. UTC

Social Media

News

Event

Kura Oncology shares are lower as the company reported Phase 1a results from its FIT-001 trial, showing a 33% to 50% response rate.

22.07.2026 г., 22:01 ч. UTC

Kura Oncology Inc. shares are lower in after-market trading, reflecting unusual volatility amid broader market fluctuations from rising crude oil prices and geopolitical tensions.

21.07.2026 г., 19:36 ч. UTC

Kura Oncology shares are higher Tuesday, amid positive market sentiment despite an earlier pullback. The stock remains below its 20-day moving average.

20.07.2026 г., 18:36 ч. UTC

Kura Oncology shares are lower today, pulling back from earlier gains amid a broader market decline linked to rising Treasury yields and geopolitical tensions.

Сравнение с други в отрасъла

Ценова промяна

Kura Oncology Inc Прогноза

Ценова цел

By TipRanks

193.73% нагоре

12-месечна прогноза

Среден 28.11 USD 193.73%

Висок 40 USD

Нисък 15 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Kura Oncology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Kura Oncology Inc през последните 3 месеца.

Настроение

By Acuity

111 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.